Review




Structured Review

Calithera inc gls inhibitor (glsi) cb839
Gls Inhibitor (Glsi) Cb839, supplied by Calithera inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gls+inhibitor+(glsi)+cb839/cb+839/pm39938153-51-0-4
Average 90 stars, based on 1 article reviews
gls inhibitor (glsi) cb839 - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

In Vivo:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Concentration Assay:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Incubation:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

RNA Sequencing:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Ex Vivo:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Spectroscopy:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Derivative Assay:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Diffusion-based Assay:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Staining:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Inhibition:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

RNA Sequencing Assay:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.

Expressing:

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier ( ) for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export
Article Snippet: GLS inhibitor (GLSi) CB839 (Calithera Biosciences, Palo Alto, CA) was formulated in dimethyl sulfoxide for cell studies or in vehicle solution as described earlier [ ] for in vivo administration.

Article Title: Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export.
Article Snippet: Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC).. Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (GLS) activity and a large pool of cellular glutamate, which mediates intracellular enrichment of cystine via xCT (SLC7A11) antiporter activity.. To overcome chemo-resistant TNBC, we identified a strategy of dual metabolic inhibition of GLS and xCT to sensitize resistant TNBC cells to chemotherapy.



Similar Products

90
Calithera inc gls inhibitor (glsi) cb839
Gls Inhibitor (Glsi) Cb839, supplied by Calithera inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gls+inhibitor+(glsi)+cb839/cb+839/pm39938153-51-0-4
Average 90 stars, based on 1 article reviews
gls inhibitor (glsi) cb839 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results